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TECHNICAL NOTE
Subclinical atherosclerosis is increased in type 2 diabetic
patients with microalbuminuria evaluated by intima-media
thickness and pulse wave velocity
HIROKI YOKOYAMA, TOMOMI AOKI, MASUMI IMAHORI, and MASAE KURAMITSU
Jiyugaoka Clinic, Internal Medicine, Obihiro, Japan
Subclinical atherosclerosis is increased in type 2 diabetic pa-
tients with microalbuminuria evaluated by intima-media thick-
ness and pulse wave velocity.
Background. Microalbuminuria appears to be a risk marker
for atherosclerosis. However, little is known about the di-
rect association between microalbuminuria and vascular wall
properties.
Methods. Subjects were 306 type 2 diabetic patients with nor-
moalbuminuria (N = 200) and microalbuminuria (N = 106).
Those who had macroalbuminuria, atherosclerotic vascular dis-
ease, and/or ankle brachial index being less than 0.9 were not
included. Brachial-ankle pulse wave velocity (PWV) was mea-
sured by automatic oscillometric method. Intima-media thick-
ness (IMT) of the common carotid artery was measured using
high-resolution B-mode ultrasonography and a computerized
image-analyzing system.
Results. Average IMT, maximum IMT, and PWV were signifi-
cantly higher in patients with microalbuminuria than in patients
with normoalbuminuria. Both average and maximum IMT in-
creased significantly as albuminuria increased in the microal-
buminuric range. Average IMT and maximum IMT correlated
significantly with PWV (P < 0.0001), although some patients
exhibited increased levels of only PWV or IMT. By a multi-
ple linear regression, age and albuminuria were independent
predictors of IMT and PWV. Waist circumference was an in-
dependent predictor of IMT. Hypertension and hemoglobin
A1c (HbA1c) were independent predictors of PWV. After ad-
justment for conventional cardiovascular risk factors including
age, sex, waist circumference, HbA1c, hypertension, hyperlipi-
demia, and smoking, albuminuria revealed a significant associ-
ation with average IMT, maximum IMT, and PWV (P < 0.05,
P < 0.0001, and P < 0.05, respectively).
Conclusion. A slight elevation of albuminuria is a significant
determinant of IMT and PWV independent of conventional
cardiovascular risk factors in type 2 diabetic patients with no
clinical nephropathy or any vascular diseases. This significant as-
sociation might point to a link in the pathogenesis of atheroscle-
rosis and diabetic nephropathy.
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Microalbuminuria is highly predictive not only for the
development of diabetic nephropathy [1] but also for
subsequent atherosclerotic vascular disease [2]. The pre-
dictive value of microalbuminuria for atherosclerotic vas-
cular disease has been shown in several epidemiologic
studies of type 2 diabetes [3], type 1 diabetes [4], and
nondiabetic populations [5]. Dysfunction of the vascular
endothelium and chronic low-grade inflammation are key
features of the initiation of atherosclerosis [6]. A num-
ber of biochemical parameters that indicate endothelial
dysfunction and chronic inflammation (i.e., von Wille-
brand factor [7], soluble vascular cell adhesion molecule
1 [7], sialic acid [8], C-reactive protein [7], and fibrino-
gen [9]) have been shown to be significantly associated
with microalbuminuria. These findings may support a
hypothesis that microalbuminuria reflects generalized
vascular damage [10, 11] which may promote atheroscle-
rosis. However the mechanism underlying the link be-
tween microalbuminuria and atherosclerotic vascular
disease is not known, and little is known on the direct
association between microalbuminuria and vascular wall
properties.
Diabetes mellitus is accompanied by a substantial in-
crease in the risk of cardiovascular disease, which ac-
counts for 70% of all deaths [12]. The fact prompts us
to detect early changes of atherosclerosis [13]. High-
resolution B-mode ultrasound imaging of intima-media
thickness (IMT) of the carotid artery has been shown to
reflect histopathologically verified atherosclerosis [14, 15]
and is, therefore, widely applied in studies of the occur-
rence and risk factors of early atherosclerosis [16]. Recent
reports have clearly indicated that an increased IMT is re-
lated to an increased risk of coronary heart disease and
stroke, even after adjustment for cardiovascular risk fac-
tors [17]. Pulse wave velocity (PWV) is another measure
of atherosclerosis. It reflects arterial stiffness [18], and it
is a marker of both the severity of vascular damage [19]
and the prognosis of atherosclerotic vascular disease in
patients with hypertension [20], end-stage renal failure
[21], and diabetes [22]. A recent report suggested that
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PWV, especially brachial-ankle PWV that can be mea-
sured automatically by oscillometric method within a few
minutes, might be useful as a marker of atherosclerotic
vascular damage and cardiovascular risk in the general
population [23]. We have previously shown the associa-
tion of albuminuria with brachial-ankle PWV in type 2
diabetic patients, including those with macroalbuminuria
and concomitant cardiovascular disease [24].
The aim of the study was to investigate (1) the relation-
ship between microalbuminuria and markers of vascular
wall properties including carotid IMT and PWV in type
2 diabetic patients, and (2) how IMT is associated with
PWV with respect to traditional cardiovascular risk fac-
tors. For this aim the study restricted patients aged 30 to
70 years and excluded those with macroalbuminuria and
concomitant cardiovascular disease. If microalbuminuria
was related to increased IMT and PWV, it would sup-
port the hypothesis which may link the pathogenesis of
atherosclerosis with diabetic nephropathy.
METHODS
The subjects were 306 Japanese patients with type 2
diabetes who visited the clinic consecutively and fulfilled
the following criteria: (1) age between 30 and 70 years, (2)
no macroalbuminuria defined as albumin-to-creatinine
(ACR) ≥300 lg/mg creatinine, and (3) no manifest con-
comitant atherosclerotic vascular disease. Albuminuria
was estimated by the mean level of the ACR measured
three times during the year. According to the mean level,
the patients were divided into those with normoalbumin-
uria (N = 200) (ACR <30 lg/mg creatinine) and with
microalbuminuria (N = 106) (ACR ≥30 and <300 lg/mg
creatinine). Patients with an ankle-brachial pressure in-
dex (ABI) less than 0.9 were not included in the study.
The study was carried out in accordance with the Helsinki
Declaration II.
Hypertension was defined by the finding on three
consecutive measurements at the clinic obtained two
weeks apart of a mean systolic blood pressure of more
than 140 mm Hg or a mean diastolic blood pressure
of more than 90 mm Hg, or both, or patients al-
ready being treated by antihypertensive drugs. Hyper-
lipidemia was defined by serum concentrations of total
cholesterol of more than 6.5 mmol/L or triglyceride of
2.3 mmol/L, or patients already being treated by lipid-
lowering agents. The hemoglobin A1c (HbA1c) level
was measured by high-performance liquid chromatogra-
phy (HPLC) (ADAMSTMA1c HA8160) (Arkray, Kyoto,
Japan), normal range, 4.3% to 5.8%. This method was
standardized by the Japan Diabetes Society and was cali-
brated every 2 weeks using GlycoHB (Kokusai Shiyaku,
Kobe, Japan) as a control. Urinary albumin and cre-
atinine were measured in random urine samples. The
urinary albumin concentration was determined by tur-
bidimetric immunoassay (TIA) with the use of a Superior-
Microalbumin kit (DPC Corporation, Tokyo, Japan) and
the urinary creatinine concentration by the Jaffe´ reac-
tion. Serum concentrations of total cholesterol, high-
density lipoprotein (HDL) cholesterol, and triglyceride
were measured by enzymatic colorimetric methods using
an automated multianalyzer (TBA-80FR) (Toshiba Med-
ical Co., Tokyo, Japan). Low-density lipoprotein (LDL)
cholesterol was calculated according to the Friedewald
formulation. The interassay variation coefficients were
5% to 8% for all assays.
Measurement of PWV
Brachial-ankle PWV was measured using a volume-
plethynographic apparatus (form PWV/ABI version-
112) (Colin, Co., Ltd., Komaki, Japan). Details of the
method, the validity, and the reproducibility have been
described previously [23, 24]. The interobserver and in-
traobserver variation coefficients were 8.4% and 10.0%,
respectively. Measurements on different days revealed
that slight changes in blood pressure did not cor-
relate with changes in PWV. The normal values of
PWV (cm/sec) in healthy subjects were 1376 ± 373
(mean ± SD) in males and 1352 ± 222 in females (N =
598, aged 45 to 75 years, mean age 61 ± 6, 373 males and
222 females).
Measurement of IMT
Ultrasound examinations were performed by three
sonographers who used the Shimadzu SDU-2200 (Shi-
madzu Co., Ltd., Kyoto, Japan) at a transducer frequency
of 5 to 10 MHz. This system provides an axial resolu-
tion of 0.30 mm. Computer-assisted acquisition, process-
ing, storage of B-mode images, and calculation of IMT
were performed with the software Intima Scope (Media
Cross, Co., Ltd., Tokyo, Japan). Both the near and far
walls of the common carotid arteries, the carotid bifurca-
tions, and the origins (first 2 cm) of the internal carotid
arteries were scanned longitudinally and transversely to
assess the occurrence of plaques [25]. The definition and
measurement of IMT were performed according to the
method reported by Pignoli et al [14]. We adopted the
scans of the far wall common carotid arteries, since sev-
eral reviews on methodological considerations of ultra-
sound investigation of IMT [26–28] have revealed that
(1) the IMT can only be measured accurately in the far-
wall position, and (2) good-quality multiple scans may be
achieved in nearly every case from the common carotid
arteries, while the percentage of missing images is high
from the internal carotid arteries.
All carotid artery measurements were performed by
the sonographers at the time of examination. The IMT
was measured by using an automated edge-detection al-
gorithm based on significant changes in density of a sec-
tion between the lumen and subadventitial structures
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perpendicular to the vessel wall. The software estimated
lines for the lumen-intima interface and the media-
adventitia interface on the basis of 30-point pixels per
3 mm obtained from the tertiary multiple regression anal-
ysis incorporating the least squares method which was de-
signed to achieve increased accuracy and reproducibility
with reduced variability for the measurements of IMT.
Two measurements on longitudinal views of both the right
and left common carotid arteries were made at the 20 mm
segment distal to the carotid bulbs. On each measure-
ment the average and maximum values were calculated
automatically. The average value of IMT was obtained on
the computerized calculation from the area detected. The
greatest value of average and maximum IMT was used as
the representative value for each individual.
The mean intraobserver and interobserver coefficients
of variation were 4.8% (range 3.0% to 5.6%) and 3.0%
(range 0.2% to 5.4%) for average IMT, and 6.0% (range
2.8% to 8.3%) and 6.4% (range 4.1% to 8.8)% for maxi-
mum IMT, respectively. The between-observer Pearson’s
correlation coefficient was r = 0.91 for average IMT, and
r = 0.91 for maximum IMT (N = 40, P < 0.0001, re-
spectively). The normal values (mm) of average IMT
measured by the above described method obtained from
healthy subjects (N = 427) were 0.51 ± 0.06 (aged 30 to
39 years), 0.55 ± 0.08 (aged 40 to 49 years), 0.61 ± 0.10
(aged 50 to 59 years), and 0.70 ± 0.14 (aged 60 to 69
years). The corresponding values of maximum IMT were
0.65 ± 0.09 (aged 30 to 39 years), 0.72 ± 0.13 (aged 40 to
49 years), 0.80 ± 0.17 (aged 50 to 59 years), and 0.88 ±
0.20 (aged 60 to 69 years).
Statistical analysis
Results are given as mean ± SD otherwise stated. The
influences of variables on PWV and IMT were explored
by simple linear (Pearson’s for continuous and Spear-
man’s for discrete variables) and multiple linear step-
wise regression analyses. Differences between relevant
groups were tested by means of Student unpaired t test
for continuous variables and the chi-squared test for dis-
crete variables. Differences in three groups were tested
by one-way analysis of variance (ANOVA). The distribu-
tion of albuminuria was normalized by logarithmic trans-
formation before statistical analysis. P values under 5%
(two-tailed) were considered to be significant. All analy-
ses were performed with the statistical software package
SPSS (SPSS Japan, Inc., Tokyo, Japan).
RESULTS
The clinical data on patients are shown in Table 1.
Patients with microalbuminuria were characterized by
higher values of HbA1c and systolic blood pressure,
and higher prevalence of hypertension and taking
Table 1. Clinical characteristics of the subjects
Normoalbuminuria Microalbuminuria
Number 200 106
% Male 73 64
Age years 55 ± 9 58 ± 8
Duration of diabetes years 7 ± 7 8 ± 7
Therapy for diabetes
% Diet 22 15
% Tablet 59 65
% Insulin 19 20
Waist circumference cm 84 ± 10 86 ± 10
Body mass index kg/m2 24.4 ± 3.4 25.6 ± 3.5
Hemoglobin A1c% 6.4 ± 0.8 6.7 ± 0.8a
Systolic blood pressure 122 ± 16 129±17a
mm Hg
Diastolic blood pressure 70 ± 10 71 ± 11
mm Hg
Albuminuriab 13 (9–19) 60 (44–105)
Serum cholesterol mmol/L 4.99 ± 0.83 5.04 ± 0.96
Serum high-density 1.42 ± 0.34 1.34 ± 0.34
lipoprotein cholesterol
mmol/L
Serum triglyceride mmol/L 1.91 ± 1.10 2.24 ± 1.42
Serum low-density 2.90 ± 0.75 2.92 ± 0.83
lipoprotein cholesterol
mmol/L
% Hypertension 34 63c
% Hyperlipidemia 32 39
% Current smoking 39 44
% Taking aspirin 9 16
% Taking angiotensin- 27 (15 ± 12) 49a (18 ± 16)
converting enzyme
inhibitors/angiotensinogen II
receptor blocker
(duration of medication)
months
% Taking calcium 15 40a
channel blockers
% Taking statin 10 14
aP < 0.01 vs. normoalbuminuria; bMedian and interquartile range are given.
angiotensin-converting enzyme (ACE) inhibitors and/or
angiotensinogen II receptor blockers (ARB), and cal-
cium channel blockers (CCB). Both average IMT and
maximum IMT were significantly higher in patients with
microalbuminuria than in patients with normoalbumin-
uria (Table 2). Similarly, PWV was significantly higher in
patients with microalbuminuria than in patients with nor-
moalbuminuria (Table 2). Both average and maximum
IMT increased significantly as albuminuria increased in
the microalbuminuric range (Table 2).
Biochemical and clinical parameters, which correlated
with at least one measure of IMT and PWV, are listed
(Table 3). Such parameters included age, duration of
diabetes, waist circumference, body mass index (BMI),
HbA1c, systolic/diastolic blood pressure, albuminuria,
serum cholesterol, serum triglyceride, and presence of
hypertension, hyperlipidemia, and plaque. Both average
IMT and maximum IMT correlated significantly with
PWV, although some patients exhibited increased levels
of only PWV or IMT (Table 3) (Fig. 1).
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Table 2. Intima-media thickness (IMT) of common carotid artery and pulse wave velocity (PWV) in type 2 diabetic patients with
normoalbuminuria and microalbuminuria
Microalbuminuria
Normoalbuminuria Microalbuminuria 1st tertile 2nd tertile 3rd tertile P valueb
Average IMT mm 0.700 ± 0.132 0.761 ± 0.159a 0.725 ± 0.128 0.738 ± 0.151 0.823 ± 0.182 0.02
Maximum IMT mm 0.843 ± 0.169 0.930 ± 0.213a 0.875 ± 0.164 0.891 ± 0.196 1.016 ± 0.249 0.009
% Plaque 21 25
PWV cm/sec 1540 ± 258 1702 ± 287a 1661 ± 283 1721 ± 282 1722 ± 300 0.61
aP < 0.0001 vs. normoalbuminuria; bOne-way analysis of variance in the microalbuminuria range.
Table 3. Simple correlation coefficients of intima-media thickness
(IMT) and pulse wave velocity (PWV) with clinical and biochemical
parameters
Average IMT Maximum IMT PWV
Age 0.47a 0.48a 0.41a
Duration of diabetes 0.10d 0.11d 0.14c
Waist circumference 0.17c 0.14c 0.14c
Body mass index 0.16c 0.14c 0.09c
Hemoglobin A1c −0.07 −0.08 0.16c
Systolic blood pressure 0.13d 0.13d 0.33a
Diastolic blood pressure −0.02 −0.04 0.20b
Albuminuria 0.23a 0.26a 0.29a
Serum cholesterol 0.14c 0.15c 0.01
Serum triglyceride 0.11d 0.12d 0.07
Hypertension 0.25a 0.27a 0.36a
Hyperlipidemia 0.17c 0.18b 0.18b
Plaque 0.32a 0.35a 0.10d
Average IMT — 0.94a 0.29a
Maximum IMT 0.94a — 0.32a
aP < 0.0001; bP < 0.001; cP < 0.01; dP < 0.05.
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Fig. 1. Association between average intima-media-thickness (IMT)
and pulse wave velocity (PWV) in type 2 diabetic patients with microal-
buminuria () and normoalbuminuria (◦) without any atherosclerotic
vascular diseases. The regression line, and the mean levels of IMT and
PWV are depicted.
A multiple linear regression analysis was performed
to establish independent predictors of IMT and PWV.
Age and albuminuria were independent predictors of av-
erage IMT, maximum IMT, and PWV (Table 4). Waist
circumference was an independent predictor of average
Table 4. Summary of stepwise multiple regression analysis for
average intima-media thickness (IMT), maximum IMT, and pulse
wave velocity (PWV)
BETA SE P value
Average IMT R2 = 0.26, F value = 36.1, P < 0.0001
Age 0.44 0.001 0.000
Waist circumference 0.14 0.001 0.004
Albuminuria 0.14 0.017 0.005
Maximum IMT R2 = 0.27, F value = 37.9, P < 0.0001
Age 0.45 0.001 0.000
Albuminuria 0.18 0.022 0.000
Waist circumference 0.11 0.001 0.024
PWV R2 = 0.29, F-value = 29.2, P < 0.0001
Age 0.38 1.7 0.000
Hypertension 0.22 29.3 0.000
Hemoglobin A1c 0.19 17.7 0.000
Albuminuria 0.13 35.3 0.000
BETA is the standardized regression coefficient and allows comparison of the
relative contribution of each variable in the prediction of the dependent variables,
and SE is the standard error of BETA. The independent variables entered were
age, waist circumference, albuminuria, hypertension, and hyperlipidemia for av-
erage IMT and maximum IMT, and age, waist circumference, hemoglobin A1c,
albuminuria, hypertension, and hyperlipidemia for PWV. Systolic/diastolic blood
pressure levels and serum concentrations of cholesterol and triglyceride were not
included because of the colinearity with the presence of hypertension and hyper-
lipidemia, respectively.
IMT and maximum IMT. Hypertension and HbA1c were
independent predictors of PWV. After adjustment for
traditional cardiovascular risk factors including age,
gender, waist circumference, HbA1c, hypertension, hy-
perlipidemia, and smoking, albuminuria revealed a sig-
nificant association with average IMT, maximum IMT,
and PWV (P < 0.05, P < 0.0001, and P < 0.05,
respectively).
DISCUSSION
This cross-sectional study has clearly shown that type
2 diabetic patients with microalbuminuria have signifi-
cantly higher values of IMT and PWV than those with
normoalbuminuria, and a slight elevation of albuminuria
is an independent determinant of IMT and PWV after
adjustment for conventional cardiovascular risk factors.
The study excluded those who had macroalbuminuria or
concomitant cardiovascular disease. Thus microalbumin-
uria is related to atherosclerosis at an early stage of the
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disease process. The significant association might point to
a link in the pathogenesis of atherosclerosis and diabetic
nephropathy.
This study is the first to show a significant association
of microalbuminuria with increased IMT in type 2 di-
abetic patients. Some preliminary studies have explored
this association, however, they studied too small numbers
and/or included patients with macroalbuminuria [29, 30].
A population-based study found a significant association
of microalbuminuria with increased IMT in nondiabetic
population (N = 991), but it was not significant in the
diabetic population (N = 450) [31]. The study defined
microalbuminuria by using single spot urine. Since the
urinary albumin excretion rate has a variation of 20% to
40%, inadequate sampling might have been a reason.
Disease process
Measures of IMT and PWV may assess the differ-
ent aspects of the atherosclerotic process [19]; the for-
mer is a structural (atherosis) and the latter a functional
(sclerosis) marker [32]. Age, duration of diabetes, waist
circumference, BMI, systemic blood pressure levels, hy-
pertension, and hyperlipidemia increased both IMT and
PWV in our study. The finding was in accordance with
the previous studies on IMT [32, 33] and on PWV [32,
34]. However, in our study where subjects were rather
well controlled for hyperglycemia (mean HbA1c of 6.5%)
and hypertension (mean systemic blood pressure of
125/70 mm Hg), PWV was influenced more by the pres-
ence of hypertension and the levels of blood pressure
and HbA1c as compared to IMT. This finding seems plau-
sible since increased blood pressure is a mechanical fac-
tor responsible for the arterial stiffening. A recent report
even indicated PWV a more precise prognostic index than
blood pressure itself by a 10-year follow-up [22]. The lack
of association between HbA1c and IMT was in keeping
with previous cross-sectional studies [32, 33], although
recent longitudinal studies have indicated a significant
effect of blood glucose control on attenuating progres-
sion of IMT [35]. It has been controversial which leads
the process of atherosclerosis between structural changes
(presence of atherosclerosis) and functional changes (ar-
terial stiffness) [19, 36]. So far there are some patients
who exhibited increased levels of only IMT or PWV, we
suggest that both mechanisms apply and that structural
changes (atherosclerosis) are not only a consequence but
may by themselves also increase arterial stiffness. This is
in accordance with the findings of E´tude du Viellissement
Arte´riel (EVA) study in which increased arterial stiffness
measured by brachial pulse pressure at baseline was as-
sociated with the progression of IMT and increased IMT
at baseline was associated with pulse pressure widening
during 4-year follow-up [37].
We presume that these putative risk factors would in-
crease IMT and PWV, leading to a slight increase of al-
buminuria. Insulin resistance may underlie this process,
since the association of insulin resistance with increased
IMT has been demonstrated in non-diabetic and type 2
diabetic populations [38, 39]. Actually waist circumfer-
ence or BMI, a strong determinant of insulin resistance,
was associated with increased IMT in the present study.
The pathogenic mechanism linking slightly elevated
urinary albumin excretion to atherogenesis is unknown.
It is hypothesized that increased urinary albumin excre-
tion reflects a generalized vascular dysfunction caused by
structural alterations, such as a reduction in the density
of heparan sulfate-proteoglycan (HS-PG) and/or the sul-
phation of HS within the extracellular matrix not only
of the glomerular basement membrane but also of the
vascular wall [10, 11]. HS-PG is synthesized in endothe-
lial and myomedial cells and is a normal constituent of
the glomerular basement membrane, endothelial vas-
cular surface, and the basement membrane of vascular
smooth muscle cells. We have previously reported that
HS in the muscle capillary basement membranes de-
creased according to the increase of albuminuria in type
1 diabetic patients, suggesting that deficient HS synthe-
sis is universal [40]. Growth factors such as transforming
growth factor-b (TGF-b), which could be extraordinar-
ily enhanced by hyperglycemia, elevated levels of sys-
temic blood pressure and intraglomerular pressure, and
glycated proteins in patients with diabetes, would affect
synthesis of extracellular matrix proteins within glomeru-
lar basement membrane and vascular wall [41]. More-
over, a number of proteins (i.e., lipoprotein lipase, tissue
factor pathway inhibitor, platelet factor 4, and antithrom-
bin III) are anchored to the vascular wall via interaction
with the chains of HS-PG [11, 42, 43]. Such alterations
may potentiate albuminuria and several of the processes
involved in atherogenesis [41].
Limitation of the study
Patients have been already treated for diabetes, hy-
pertension, and hyperlipidemia. Thus the relationship
between the obtained values of blood pressure, lipid pro-
files, and HbA1c with IMT and PWV were likely con-
founded by the treatment. Actually it was weak as shown
in Table 3 while the presence of hypertension and hy-
perlipidemia indicated a stronger relationship. Both IMT
and PWV did not differ between users and nonusers of as-
pirin, as well as of ACE inhibitors/ARB, CCB, and statin
(data not shown). We were unable to find any effect of
duration of ACE inhibitors/ARB medication on IMT and
PWV. This fact may at least indicate that the use of these
drugs did not confound the main outcome (i.e., a signif-
icant association of albuminuria with IMT and PWV).
The effect of these drugs on IMT and PWV surely cannot
be evaluated in a cross-sectional study. Smoking failed to
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show a significant effect on IMT and PWV. This might be
due to the rough classification of smoking status in our
study.
CONCLUSION
Microalbuminuria is a significant determinant of an in-
crease in IMT and PWV independent of conventional
cardiovascular risk factors. Conventional cardiovascular
risk factors are linked to an increase in both PWV and
IMT. This process is likely an early stage of atherosclero-
sis. The significant association might point to a link in the
pathogenesis of atherosclerosis and diabetic nephropa-
thy. Whether these measures of subclinical atheroscle-
rosis can enable better-tailored medical care will need
further studies. However, it would be important to incor-
porate measurements of IMT and PWV in daily practice
since (1) they can detect an early stage of atherosclerosis
in high-risk population, and (2) if the levels are increased,
more intensive therapy not only for hyperglycemia but
also for hypertension, dyslipidemia, and obesity should
be applied with an aim to prevent future cardiovascular
events.
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